BCMA bispecific

DRUG2 trials

Sponsors

Case Comprehensive Cancer Center, Centre Hospitalier Universitaire de Saint Etienne

Conditions

Amyloid Light-chain AmyloidosisMyeloma Multiple

Phase 1

A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

Not yet recruitingNCT07612787

Centre Hospitalier Universitaire de Saint EtienneMyeloma Multiple

Start: 2026-06-01End: 2031-01-01Target: 44Updated: 2026-06-15

Phase 2

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Not yet recruitingNCT07524634

Case Comprehensive Cancer CenterAmyloid Light-chain Amyloidosis

Start: 2026-06-01End: 2031-06-01Target: 64Updated: 2026-04-24